[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hdv\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hdv":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,71,98],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100580198","non-interventional-study-to-assess-the-number-of-people-with-untreatedunknown-hbv--hdv-and-hcv-in-south-east-austria-100580198",false,"NCT06834178","Non-interventional Study to Assess the Number of People With Untreated\u002FUnknown HBV + HDV and HCV in South-East Austria","Hepatitis Elimination And Liver Care in South-East Austria (HEAL-S)","HEAL-S","Inclusion Criteria:\n\n* The target population for the HCV cohort consists of individuals with detectable plasma HCV RNA at the latest observation.\n* The target population for the HBV cohort consists of individuals with detectable plasma HBV RNA at any time and no recorded HDV testing or a positive HDV serology.\n\nExclusion Criteria:\n\n* No valid SVRN (german: Sozialversicherungsnummer, english: Social insurance number)\n* No contact details available\n* Documented Sustained Virological Response (HCV cohort)\n* Documented assessment of HDV status (HBV cohort)","ALL",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","The HEAL-S study is a non-interventional study with retrospective data analysis. It consists of two parts. First a retrospective analysis based on nucleic acid testing (NAT) results will be performed. Two cohorts (HCV) and (HBV) will be established. Patients falling into one (or both) of the two cohorts will be invited to a prospective linkage-to-care study. In this part, patients are invited to the clinic, where the possibility of hepatitis treatment will be discussed.",[24,25,26,27,28,29],"HBV","HCV","HDV","Coinfection","Hepatitis B Coinfection","Hepatitis B",[24,25,26,31,32,29,33,34],"Hepatitis B and D coinfection","untreated hepatitis","Hepatitis C","Hepatitis treatment","RECRUITING","2026-06-17",{"date":38,"type":39},"2026-06-18","ACTUAL",{"date":41,"type":39},"2025-05-01",{"date":43,"type":20},"2026-10",{"name":45,"class":46},"Vanessa Stadlbauer-Koellner, MD","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":47},"100626986","epro-diary---hdv--macroliver--100626986","NCT07442760","ePro Diary - HDV ( MACROLIVER )","The Patient is the Main Protagonist of His Care Journey","Inclusion Criteria:\n\n* Age \\> 18 years\n* Diagnosis of Delta infection (anti-HDV positivity)\n* Signed informed consent\n* Ability to adequately understand instructions for correctly using mobile device applications.\n\nExclusion Criteria:\n\n* Refusal or inability to provide informed consent.","18 Years",{"count":57,"type":20},55,"This study is part of the MACROLIVER Project, which aims to develop a digital tool for patients and their caregivers to manage liver diseases. Approximately 20-25 million individuals worldwide carry HBsAg and are co-infected with HDV, though geographic variations exist. In Italy, an estimated 10,000-20,000 individuals are affected by Delta hepatitis (HD). These data are approximate, given the absence of current population studies and effective screening methods.\n\nAlthough considered rare, chronic HD (CHD) is the most aggressive form of viral hepatitis, with most patients progressing rapidly to end-stage liver disease or developing hepatocellular carcinoma at a young age, often requiring liver transplantation. Screening HBsAg-positive patients for Delta co-infection is not widespread, leading to late diagnoses. Additionally, accurate quantification of viral RNA is limited to a few specialized centers.\n\nThe lack of effective antiviral therapies has led many Delta hepatitis patients to frequently switch hepatology centers in search of treatments or to miss regular medical check-ups. However, HDV management may change significantly following the recent EMA approval of a new antiviral drug, bulevirtide-an entry inhibitor administered subcutaneously daily-reimbursed in Italy since April 2023. This drug has shown promising results in Phase II and III studies, including in cirrhotic patients with severe portal hypertension.\n\nThe COVID-19 pandemic exacerbated this situation, causing reduced access to healthcare facilities and negatively impacting patients with chronic diseases. However, it also accelerated the search for effective, high-quality digital solutions for patient management.\n\nThe ePro-Diary HDV proposes to facilitate continuous communication between patients and doctors, monitor key lab values, quality of life questionnaires, and overall health status by an application for mobile phone.\n\nThe objectives are twofold: to make patients active participants in their care-enhancing retention and adherence through an \"active App-based approach\"-and to evaluate changes in patient quality of life with this \"active\" remote approach. This tool will support clinicians and patients without replacing standard clinical monitoring.",[26,60,61],"HDV Infection","Hepatitis","2026-02-24",{"date":64,"type":39},"2026-03-02",{"date":66,"type":39},"2025-03-31",{"date":68,"type":20},"2030-03-31",{"name":70,"class":46},"FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":78,"targetDuration":80,"studyType":21,"phases":4,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":5},"100528427","d-solve-cohorts-cohort-a-and-b-100528427","NCT06160635","D-SOLVE Cohorts (Cohort a and B)","HDV750","Inclusion Criteria:\n\n* Anti-HDV positive\n* ≥18 years old\n* Sex: m\u002Ff\u002Fd\n* Informed consent for prospective procedures\n\nExclusion Criteria:\n\n* Anti-HDV negative",{"count":79,"type":20},750,"3 Years","Hepatitis D is by far the most severe form of chronic viral hepatitis, frequently leading to liver failure, hepatocellular carcinoma and death. Hepatitis D is caused by coinfection Hepatitis D is caused by co-infection with hepatitis B virus (HBV) and hepatitis D virus (HDV).\n\nThis multicenter cohort should enable a comprehensive and unbiased biomarker screening of well-defined HDV-infected patients, followed by mechanistic studies to determine the functional role of distinct molecules. Patient surveillance strategies and antiviral treatment approaches could be personalized which should reduce clinical and social disease burden, improve quality of life and save direct and indirect costs caused by HDV infection.",[26,60,83],"Chronic Liver Disease",[26,85,86,87,88],"Hepatitis Delta","chronic liver disease","patient cohort","biomarker","2025-03-11",{"date":91,"type":39},"2025-03-12",{"date":93,"type":39},"2023-02-22",{"date":95,"type":20},"2026-09-30",{"name":97,"class":46},"Hannover Medical School",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":107,"conditions":108,"keywords":109,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":5},"100466218","thailand-hdv-cohort-100466218","NCT05350865","Thailand HDV Cohort","Prevalence, Risk Factor and Clinical Significance of Hepatitis D Virus Infection Among Targeted High Risk Population in Thailand: Nationwide Survey 2022-2024","Inclusion Criteria:\n\n1. Male or female, aged 18 years and older\n2. Chronically-infected with HBV, as defined by:\n\n   Positive Hepatitis B surface antigen HBsAg) or HBV DNA result with a subsequent positive HBsAg or HBV DNA result at least 6 months after first positive result\n3. Provide signed and dated informed consent form.\n\nExclusion Criteria:\n\nNon chronic HBV",{"count":106,"type":20},3152,"There is very limited data of HDV in Thailand. As both HDV and HIV can accelerate the HBV course and increased the risk of death, particularly, among those with low CD4 cells\u002Fcount, therefore, HDV burden in this special population is unmet need. Therefore, this study plans to perform a nationwide survey of the prevalence and predictor of HDV among people uses drugs (PWID) with and without HIV, HBV\u002FHIV (MSM vs non MSM), HBV related cirrhosis. Findinds from this study will provide the scientific community to understand how important HDV is among HBV patients, this could be used to develop strategies for HDV screening and treatment",[26],[24,26,110,111],"cirrhosis","Thailand","2024-09-30",{"date":114,"type":39},"2024-10-02",{"date":116,"type":39},"2023-01-30",{"date":118,"type":20},"2025-05",{"name":120,"class":46},"The HIV Netherlands Australia Thailand Research Collaboration"]